Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:

NCT ID: NCT01881919 Completed - Diabetes Clinical Trials

Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial

Start date: February 2013
Phase: Phase 0
Study type: Interventional

The purpose of this study was to test the effect of chronic consumption of Quercetin 500 mg tablets on blood uric acid and other biomarkers in adult males.

NCT ID: NCT01872832 Completed - Gout Clinical Trials

Single and Multiple Dose Study in Japanese Subjects

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This study will explore the safety, tolerability, and serum uric acid lowering effect of RDEA3170 in healthy Japanese males to allow comparison with the Western population.

NCT ID: NCT01830725 Completed - Gout Clinical Trials

Purine Metabolism Enzyme SNP to Uric Acid Production

Start date: December 2012
Phase: N/A
Study type: Observational

Determine whether a relationship exists between polymorphisms of the genes XDH, HPRT1, and PRPS1 and gout, hyperuricemia, or the dose of xanthine oxidase (XO) inhibitors to reach a goal serum uric acid of less than 6 mg/dL. This study is observational in nature as no dose adjustment of XO inhibitors will be made by study investigators.

NCT ID: NCT01808144 Completed - Gout Clinical Trials

Lesinurad and Febuxostat Combination Extension Study in Gout

Start date: March 1, 2013
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.

NCT ID: NCT01808131 Completed - Gout Clinical Trials

Lesinurad and Allopurinol Combination Extension Study in Gout

Start date: February 2013
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with allopurinol over a long-term timeframe.

NCT ID: NCT01744379 Completed - Gout Clinical Trials

Single and Multiple Dose Study in Japanese

Start date: December 2012
Phase: Phase 1
Study type: Interventional

This study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy Japanese males to allow comparison with the Western population.

NCT ID: NCT01736514 Completed - Gout Clinical Trials

A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

Start date: March 2011
Phase: Phase 3
Study type: Interventional

This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.

NCT ID: NCT01712204 Completed - Gout Flares Clinical Trials

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis. The efficacy of IL-1β blockade in the prophylaxis of gouty flares during initiation of ULT has been validated in multiple trials of IL-1β inhibitor therapies. Therefore, it is believed that IL-1β is a relevant therapeutic target for gout flares. AC-201 is an IL-1β modulator indicated for the treatment of osteoarthritis with good safety record and very few contraindications to the co-morbidities commonly among gout patients. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.

NCT ID: NCT01685424 Completed - Clinical trials for Rheumatoid Arthritis

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Start date: June 30, 2006
Phase:
Study type: Observational

This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).

NCT ID: NCT01654276 Completed - Gout Clinical Trials

Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome

Start date: May 2012
Phase: Phase 4
Study type: Interventional

This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol) by lowering uric acid levels in the blood.